Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Mersana is under investigation for potential breaches of fiduciary duty related to its transaction with Day One Biopharmaceuticals, which may not be in the best interest of all shareholders [1][3]. Transaction Details - Mersana shareholders will receive $25.00 per share in cash upfront, with potential contingent value rights payments of up to $30.25 per share, leading to a total equity value of approximately $129 million at closing and a total deal value of up to approximately $285 million if all milestone payments are achieved [2]. - The contingent payments are linked to clinical development, regulatory, and commercial milestones for Mersana's B7-H4-directed antibody-drug conjugate Emi-Le [2]. Board Conduct - The transaction agreement imposes significant penalties on Mersana for accepting competing bids, raising concerns about the board's fulfillment of fiduciary duties to shareholders [3].